Press release
Janssen Pharmaceutica NV and Proteros expand relationship and enter into Global Agreement
Martinsried Jan 09, 2012. Janssen Research & Development, a division of Janssen Pharmaceutica NV (“Janssen”) and Proteros biostructures GmbH (“Proteros”) today announced they have entered into a long-term global service agreement granting Janssen privileged access to Proteros portfolio of discovery technologies and services.Under the agreement Janssen will have broad access to Proteros’ drug discovery technologies, including structural biology, biophysical screening and profiling service, novel fragment libraries, medicinal chemistry expertise and fully integrated structure-based lead discovery programs to identify small molecule inhibitors. This is a consolidation of the services Proteros has provided over the past eight years in support of Janssen discovery research efforts in the USA and Europe.
Dr Torsten Neuefeind, Chief Executive Officer for Proteros commented “it is an important milestone for Proteros that the work performed by our scientists to support Janssen global discovery research is recognized as being of such high value that is has developed into this strategic collaboration. Proteros looks forward to contributing innovations and high quality science that makes a positive impact on Janssen’s research success”.
About Proteros
Proteros is a privately held company, which provides services and proprietary technologies to support integrated drug discovery. The company accelerates and improves protein structure analysis and structure-based drug discovery with its expertise, industrialized processes and unique technologies for crystallography and fragment-based lead generation. Proteros complements its clients’ internal capabilities with external expertise and access to flexible resources. Proteros currently provides services for more than 80 pharmaceutical and biotechnology clients in North America, Europe and Asia.
For further information please visit the website at: www.proteros.com
Proteros biostructures GmbH
Thomas Waldmann, Ph.D.
Bunsenstrasse 7a
D-82152, Martinsried
Germany
Phone: +49 89 7007 61 – 0
E-Mail: business@proteros.com
Internet: www.proteros.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Janssen Pharmaceutica NV and Proteros expand relationship and enter into Global Agreement here
News-ID: 206470 • Views: …
More Releases from Proteros biostructures GmbH
PROTEROS ANNOUNCES SUCCESSFUL CLOSE OF FINANCING ROUND
Largest-ever Financing allows for Expansion of Drug Discovery Capabilities
MARTINSRIED, GERMANY (August 6th, 2012) – Proteros biostructures GmbH (‘Proteros’) announced today that it had successfully closed a financing round of five million Euros to fund the continued expansion and growth of the company.
The financing round was led by BayBG, a key equity investor for Proteros. The financing round is the third and largest investment into the firm since the inception…
Proteros and Eisai Co., Ltd enter into Integrated Lead Discovery Collaboration
Martinsried (Germany), April 16, 2012. Proteros biostructures GmbH today announced that the company has entered into a research collaboration with Eisai Co., Ltd (Japan) to identify small molecule inhibitors against a target selected by Eisai in the field of immunology.
Under the agreement Proteros will deliver a novel lead compound applying its integrated lead discovery platform that includes X-Ray structural biology, biophysical screening and profiling, novel fragment libraries and medicinal chemistry…
Proteros announces the appointment of Dr. Klaus Hinterding as Chief Scientific O …
Martinsried, Germany, February 9, 2012. Proteros biostructures GmbH (Proteros) announced today that Dr. Klaus Hinterding, formerly at Hoffmann-La Roche Ltd. (Roche), has joined the company as Chief Scientific Officer and member of the management board. Dr. Hinterding brings to Proteros considerable pharmaceutical industry experience that spans early research through to clinical development in various therapeutic areas.
At Novartis, his research contributed to the understanding of the mode-of-action of GilenyaTM, licensed for…
More Releases for Jan
JAN-PRO Cleaning & Disinfecting Expands Austin Commercial Cleaning Services
Image: https://www.globalnewslines.com/uploads/2025/04/1744049025.jpg
JAN-PRO Cleaning & Disinfecting, a leader in professional cleaning solutions, continues to set the standard for high-quality Austin Commercial Cleaning. Businesses across various industries benefit from a commitment to superior cleanliness, advanced disinfecting techniques, and eco-friendly solutions.
With a reputation built on excellence and trust, JAN-PRO Cleaning & Disinfecting delivers Austin Commercial Cleaning Service [https://www.google.com/maps?cid=16796184187958128780] that meets the highest industry standards. From office buildings to healthcare facilities, each space receives…
2 New Articles from Happy Smoking - JAN 2025
Happy Smoking is your definitive guide to smoking culture, providing expert reviews, comprehensive guides, and a platform for aficionados to connect and share their passion. We offer responsible, accurate information on enjoying cigars, pipes, and hookahs.
Austin, TX - JAN 2025: Happy Smoking, a leader in smoking guides and expert reviews, is thrilled to announce the publishing of two new articles on our platform. This month's update includes a diverse range…
Healthcare Product Summit 2020, 25th Jan , Hyderabad
Sangam of Healthcare , IT and Innovations . Its an opportunity for large institutions, corporate organizations, disruptive SMEs, start-ups to team up, reinforce their innovative power and harmonize with each other to derive amazing solutions.
Let’s ReThink Health. And care. The 3rd Edition of Healthcare Product Summit 2020 attracts healthcare and technology enthusiasts to discuss and debate about challenges and opportunities in modern healthcare. The one-day conference will be held on…
New Book By Jan Marin Tramontano: What Love Becomes
ADELAIDE BOOKS is proud to offer the latest work by Jan Marin Tramontano What Love Becomes hitting stores everywhere on February 7th, 2019.
What Love Becomes is a work of literary fiction that traces the intimate landscape of two contemporary marriages from their idealistic, yet misguided beginnings. Each couple mistakenly believes their happily ever after will come without really knowing who’ve they’ve married. What begins as self-deception quickly morphs into deception…
Datamax-O’Neil Appoints Jan Mariën Product Manager EMEA
Experienced expert for printing solutions supports customized product development for the EMEA market
BOURG-LÈS-VALENCE, FRANCE – Datamax-O’Neil, a leading manufacturer of stationary, vehicle mount, portable label and receipt printers, has named Jan Mariën as Product Manager EMEA. The new position has been created to even better fulfil the special requirements of customers in Europe, the Middle East and Africa. Jan Mariën is managing the development of Datamax-O’Neil’s product lines in the…
Intel Teach endorsed by EU Commissioner Jan Figel
At the high-level European EMINENT Conference in Brussels, held from Dec 06-07 2007, EU Commissioner Ján Figel, responsible for Education, Training, Culture and Youth, stressed the importance of a methodological approach in Professional Development for Teachers. “Digital Competence is a pre-requisite to learn learning” he said in front of over 250 delegates from around the world. “Learning to learn is a crucial competence for teachers, who are the most critical…
